RTW INVESTMENTS, LPRTW INVESTMENTS, LP

Institutional investor · Portfolio as of Q1 2025

SEC EDGAR SourceSEC Filings

Top Holdings68 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction

MADRIGAL PHARMACEUTICALS INC

2M$660.4M10.1%$265.36+23.55%
8 qtrssince 2023-Q2
Unchanged
0
ARGXARGX
ADR

ARGENX SE - ADR

673,497$398.6M6.1%$356.02+66.24%
25 qtrssince 2019-Q1
Unchanged
0

PTC THERAPEUTICS INC

7.5M$381.3M5.8%$43.52+24.64%
25 qtrssince 2019-Q1
Increased
61

NATERA INC

2.6M$366.8M5.6%$42.12+241.71%
23 qtrssince 2019-Q3
Increased
60

AXSOME THERAPEUTICS INC

2.9M$340.9M5.2%$62.01+91.14%
25 qtrssince 2019-Q1
Decreased
0
AKROAKRODelisted

AKERO THERAPEUTICS INC

7.4M$300.3M4.6%$26.19+63.12%
6 qtrssince 2023-Q4
Increased
61

PROTAGONIST THERAPEUTICS INC

5.7M$276.6M4.2%$24.15+102.38%
23 qtrssince 2019-Q3
Increased
59
8.7M$258.2M3.9%$26.19+20.64%
20 qtrssince 2020-Q2
Increased
62

PENUMBRA INC

862,770$230.7M3.5%$249.61+7.19%
15 qtrssince 2021-Q3
Increased
56

INSMED INC

3M$230M3.5%$44.25+76.23%
8 qtrssince 2023-Q2
Unchanged
0

ALKERMES PLC

6.9M$227.3M3.5%$27.26+21.14%
7 qtrssince 2023-Q3
Decreased
0

STRYKER CORP

590,221$219.7M3.4%$356.25+1.38%
3 qtrssince 2024-Q3
Unchanged
0
VRNAVRNADelisted
ADR

VERONA PHARMA PLC

2.8M$180.9M2.8%
2 qtrssince 2024-Q4
Increased
74
MRUSMRUSDelisted

MERUS N V

4.2M$175.5M2.7%$34.06+30.99%
8 qtrssince 2023-Q2
Unchanged
0

TARSUS PHARMACEUTICALS INC

3.3M$170.3M2.6%$33.23+55.69%
18 qtrssince 2020-Q4
Increased
53
IMCRIMCR
ADR

IMMUNOCORE HLDGS PLC

4.9M$144.5M2.2%$43.05-31.29%
17 qtrssince 2021-Q1
Unchanged
0

ACADIA Pharmaceuticals Inc.

8.5M$141.9M2.2%$18.35-6.97%
12 qtrssince 2022-Q2
Decreased
0

ROCKET PHARMACEUTICALS INC

17.7M$118M1.8%$18.79-59.61%
25 qtrssince 2019-Q1
Unchanged
0

RadNet, Inc.

2.3M$115.2M1.8%$47.21+4.73%
6 qtrssince 2023-Q4
Increased
55
MASIMASIDelisted

MASIMO CORP

683,294$113.8M1.7%$174.28-6.16%
25 qtrssince 2019-Q1
Unchanged
0
$6.5B
AUM
68
Positions
Q1 2025
Filing
Rating · 3.0
Quarterly Portfolio Change
+35%Q4'23$6.4B+6%Q1'24$6.8B-5%Q2'24$6.5B+7%Q3'24$6.9B-4%Q4'24$6.6B-1%Q1'25$6.5B
Activity profile
$ moved · Q1'25
New21%Increased45%Decreased16%Exited19%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.4 years
<1Q10%1-4Q22%1-2Y26%2Y+41%

RTW INVESTMENTS, LP manages $6.5B across 68 positions as of Q1 2025. Top holdings: MDGL (10.1%), ARGX (6.1%), PTCT (5.8%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.

Q1 2025 Summary

Active quarter - 10 new positions, 14 exits, 17 increased. Top move: VRNA (INCREASED, conviction 74). Portfolio: $6.5B across 68 positions.

Top holdings by portfolio weight

Total AUM$7B
MDGL10.10%
ARGX6.10%
PTCT5.83%
NTRA5.61%
AXSM5.21%
AKRO4.59%
PTGX4.23%
RNAM3.95%
PEN3.53%
INSM3.52%
Other3.48%

Portfolio allocation by GICS sector

Sectors3
Healthcare92.05%
Unknown7.84%
Financial Services0.12%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare
Compare DNA across all funds
7-dimension quality assessment
Solid(3.0 / 5.0)
Track Record36
Conviction45
Concentration72
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
RDNTRDNTRadNet, Inc.
Q4 2024 Q2 2026+3M shares+$173.4M
6Q
CMPSCMPSCOMPASS PATHWAYS PLC
Q1 2025 Q2 2026+7.6M shares+$139.7M
6Q
IMTXIMTXIMMATICS N.V
Q1 2025 Q2 2026+6.4M shares+$84.6M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used